Patients planning to use Hanmi Pharmaceutical's GLP-1 obesity treatment must be aware of certain safety rules. There is much to check, including concurrent use with diabetes medications, high-dose administration, adolescent use, pregnancy and breastfeeding, and pregnancy plans. The safety guidance material 'Using GLP-1 Obesity Treatments Safely,' released by the Ministry of Food and Drug Safety (MFDS), contains five questions and precautions that patients may be curious about.

1. If taking diabetes medication... beware the risk of hypoglycemia

The first issue concerns the use of obesity treatments by patients taking diabetes medication. According to the MFDS guidance, if a patient taking diabetes medication starts using a GLP-1 obesity treatment, the risk of blood sugar dropping too low may increase. In such cases, dosage adjustment of the concurrent medication may be necessary, so patients must consult with their healthcare provider.

2. Can treatment start at a high dose?... Increase slowly according to the prescribed dosage and schedule

The second concerns the starting dosage. The MFDS advises that administering a high dose from the beginning can cause serious side effects. Dosage should be increased slowly according to the prescribed dosage and schedule, determined in consultation with healthcare providers, so the body can adapt to the medication.

3. Adolescent administration... impact on growth and development must be examined

The third is the issue of administration to adolescents. Adolescence is a period of ongoing growth and development, requiring different precautions than for adults. In particular, it is necessary to check whether insufficient nutritional intake or weight loss affects growth, and to consult healthcare providers about adverse reactions such as dehydration due to nausea and vomiting, or acute pancreatitis. However, whether the drug can be used for adolescents must be determined according to the approved labeling of each individual product and the patient's condition.

4. If pregnant or breastfeeding... discontinue use and consult a healthcare provider

The fourth concerns administration during pregnancy and breastfeeding. Hanmi Pharmaceutical advises that patients who are pregnant or breastfeeding, or planning pregnancy, should discontinue use and consult a healthcare provider. In particular, it emphasized that expert consultation is necessary during pregnancy, as sufficient evidence has not yet been established.

5. When to stop treatment when planning pregnancy... at least 2 months for semaglutide, 1 month for tirzepatide

Finally, there is the timing of discontinuation in relation to pregnancy plans. According to the guidance material, considering how long the drugs remain in the body, contraception should be used for at least 2 months after discontinuing semaglutide and at least 1 month after discontinuing tirzepatide. This guidance reflects the differences in how long each drug remains in the body.

Arbitrary dosage changes or schedule adjustments prohibited... thorough consultation with healthcare providers needed

This material shows that in the use of obesity treatments, not only weight-loss efficacy but also safety management based on administration methods and patient condition is important. In particular, patients taking medications for existing conditions or preparing for pregnancy need to thoroughly discuss the timing of starting and stopping treatment with their healthcare providers. GLP-1 obesity treatments must not be used with arbitrarily changed dosages or adjusted administration schedules simply for the purpose of losing weight. Comprehensive consideration of side effect possibilities, concurrent medications, and the patient's health status, along with treatment efficacy, is key to safe drug use.

[This article was written based on the GLP-1 obesity treatment safety guidance material provided by the Ministry of Food and Drug Safety. Approved labeling and conditions of use may differ by product, and actual administration and discontinuation should follow the judgment of healthcare professionals. AI assistance was used in the writing of this article.]